240 related articles for article (PubMed ID: 22710717)
1. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation.
Liu Z; Zanata SM; Kim J; Peterson MA; Di Vizio D; Chirieac LR; Pyne S; Agostini M; Freeman MR; Loda M
Oncogene; 2013 Mar; 32(13):1660-9. PubMed ID: 22710717
[TBL] [Abstract][Full Text] [Related]
2. Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8.
Cai J; Crotty TM; Reichert E; Carraway KL; Stafforini DM; Topham MK
J Biol Chem; 2010 Mar; 285(10):6952-9. PubMed ID: 20064931
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer.
Kim J; Kim WJ; Liu Z; Loda M; Freeman MR
Cell Cycle; 2012 Mar; 11(6):1123-30. PubMed ID: 22370483
[TBL] [Abstract][Full Text] [Related]
4. The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
Lu Y; Sun Y; Zhang J; Kong M; Zhao Z; Sun B; Wang Y; Jiang Y; Chen S; Wang C; Tong Y; Wen L; Huang M; Wu F; Zhang L
Cancer Lett; 2024 Aug; 596():217020. PubMed ID: 38849009
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.
Xiong B; Huang J; Liu Y; Zou M; Zhao Z; Gong J; Wu X; Qiu C
Cell Oncol (Dordr); 2021 Apr; 44(2):329-343. PubMed ID: 33074477
[TBL] [Abstract][Full Text] [Related]
6. USP2a protein deubiquitinates and stabilizes the circadian protein CRY1 in response to inflammatory signals.
Tong X; Buelow K; Guha A; Rausch R; Yin L
J Biol Chem; 2012 Jul; 287(30):25280-91. PubMed ID: 22669941
[TBL] [Abstract][Full Text] [Related]
7. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
Walsh AM; Lazzara MJ
Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
[TBL] [Abstract][Full Text] [Related]
8. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes.
Mizuno E; Iura T; Mukai A; Yoshimori T; Kitamura N; Komada M
Mol Biol Cell; 2005 Nov; 16(11):5163-74. PubMed ID: 16120644
[TBL] [Abstract][Full Text] [Related]
9. MdmX is a substrate for the deubiquitinating enzyme USP2a.
Allende-Vega N; Sparks A; Lane DP; Saville MK
Oncogene; 2010 Jan; 29(3):432-41. PubMed ID: 19838211
[TBL] [Abstract][Full Text] [Related]
10. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer.
Benassi B; Flavin R; Marchionni L; Zanata S; Pan Y; Chowdhury D; Marani M; Strano S; Muti P; Blandino G; Loda M
Cancer Discov; 2012 Mar; 2(3):236-47. PubMed ID: 22585994
[TBL] [Abstract][Full Text] [Related]
11. Lysine 63-linked polyubiquitination is required for EGF receptor degradation.
Huang F; Zeng X; Kim W; Balasubramani M; Fortian A; Gygi SP; Yates NA; Sorkin A
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15722-7. PubMed ID: 24019463
[TBL] [Abstract][Full Text] [Related]
12. The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms.
Wang T; Zhang J; Wang S; Sun X; Wang D; Gao Y; Zhang Y; Xu L; Wu Y; Wu Y; Liu F; Liu X; Liu S; Zhang Y; Wang Y; Zou L; Liu H
Cell Commun Signal; 2018 Jul; 16(1):40. PubMed ID: 29976202
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Nakagawa T; Husni RE; Sakashita S; Takeuchi T; Noguchi M
Pathol Int; 2017 Jun; 67(6):292-301. PubMed ID: 28544031
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.
Shi Y; Solomon LR; Pereda-Lopez A; Giranda VL; Luo Y; Johnson EF; Shoemaker AR; Leverson J; Liu X
J Biol Chem; 2011 Nov; 286(45):38960-8. PubMed ID: 21890637
[TBL] [Abstract][Full Text] [Related]
15. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866
[TBL] [Abstract][Full Text] [Related]
16. USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells.
McCann AP; Smyth P; Cogo F; McDaid WJ; Jiang L; Lin J; Evergren E; Burden RE; Van Schaeybroeck S; Scott CJ; Burrows JF
Cell Commun Signal; 2018 Nov; 16(1):77. PubMed ID: 30409180
[TBL] [Abstract][Full Text] [Related]
17. De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1.
Mahul-Mellier AL; Datler C; Pazarentzos E; Lin B; Chaisaklert W; Abuali G; Grimm S
Biochim Biophys Acta; 2012 Aug; 1823(8):1353-65. PubMed ID: 22659130
[TBL] [Abstract][Full Text] [Related]
18. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Nishimura Y; Yoshioka K; Bereczky B; Itoh K
Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
[TBL] [Abstract][Full Text] [Related]
19. The isopeptidase USP2a protects human prostate cancer from apoptosis.
Priolo C; Tang D; Brahamandan M; Benassi B; Sicinska E; Ogino S; Farsetti A; Porrello A; Finn S; Zimmermann J; Febbo P; Loda M
Cancer Res; 2006 Sep; 66(17):8625-32. PubMed ID: 16951176
[TBL] [Abstract][Full Text] [Related]
20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
